Presentation on Early Clinical Response to Sonata™ System Selected as Best Abstract In New Instrumentation/Technology Category
Redwood City, CA—November 12, 2015 – Gynesonics, Inc., a women’s health technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of uterine fibroids, announced today that its Sonata™ System technology platform for the transcervically delivered incision-free treatment of uterine fibroids will be featured in five presentations at the 44th Annual American Association of Gynecologic Laparoscopists (AAGL) Global Congress to be held November 15-19 at the MGM Grand Conference Center in Las Vegas. The AAGL is the leading medical association promoting minimally invasive gynecologic surgery among surgeons, with over 7,000 members representing 110 countries worldwide.
One of the presentations focused on the Sonata System, titled “Early Clinical Response to Intrauterine Ultrasound-Guided Transcervical Radiofrequency Ablation” to be presented by Sebastiaan Veersema, M.D., Ph.D., has been selected as the winner of the Daniel F. Kott Award for the Best Abstract on New Instrumentation or Technology. The abstract, one of 33 accepted for the conference in the New Instrumentation or Technology category, was acknowledged by the AAGL for “excellent research in advancing minimally invasive gynecology.”
Of the 50-patient study, Dr. Veersema and his co-authors concluded that the Sonata System “produced significant clinical benefits including reduction in menstrual bleeding, within three months in the majority of patients.”
“The range of presentations accepted by the AAGL Congress regarding the Sonata platform describes its potential for advancing patient care. It is also emblematic of the strong clinician interest we are seeing in our Sonata System, our enhanced, next generation technology platform for the incision-free treatment of uterine fibroids,” said Gynesonics President and CEO Christopher M. Owens. “The presentations demonstrate that our technology is performing well, producing compelling outcomes.”
Topics and Presenters by Day and Time (Pacific Standard Time):
Tuesday, November 17: Open Communications 6 – New Instruments, 2:15 – 3:15 pm, Room 115
1. Correlation of Reductions in Perfused Fibroid Volume With Subsequent Reductions in Total Fibroid Volume After Transcervical Radiofrequency Ablation – Marlies Bongers, M.D., Ph.D., Maxima Medical Center, Eindhoven, Netherlands
2. Early Clinical Response to Intrauterine Ultrasound-Guided Transcervical Radiofrequency Ablation – Sebastiaan Veersema, M.D., Ph.D., St. Antonius Hospital, Utrecht, Netherlands
3. The SONATA Study: Sonography-Guided Transcervical Ablation of Uterine Fibroids – Gretchen Makai, M.D., Christiana Care Health System, Newark, Delaware Wednesday,
November 18: Open Communications 21 – New Instruments, 3:20-5:00 pm, Room 112/113
4. Longitudinal Course of Fibroid Volume Reduction and Symptom Relief After Transcervical Radiofrequency Ablation – Jose Garza-Leal, M.D., Hospital Universitario “Dr. José Eleuterio González” de Universidad Autonoma de Nuevo León, Monterrey, Mexico
Virtual Poster: Congress Day 1 and 2, 11:00 am – 5:00 pm
5. Normal Pregnancy Outcome after Transcervical Radiofrequency Ablation of Uterine Fibroids – Jose Garza-Leal, M.D.
About Sonata System
The Sonata™ System, the next generation of Gynesonics’ technology platform (the previous generation referred to as VizAblate), uses radiofrequency energy to ablate fibroids under intrauterine sonography guidance. The Sonata™ System, including the SMART Targeting Guide, enables the gynecologist to target fibroids and optimize ablations within them. Sonata™ System’s design provides a straightforward, transcervical access for a uterus preserving, incision-free fibroid treatment. This intrauterine approach is designed to avoid the peritoneal cavity. In October 2014, Gynesonics announced FDA approval of the SONATA IDE pivotal trial for their latest generation Sonata™ System.
Gynesonics is a women’s healthcare company focused on minimally invasive solutions for symptomatic uterine fibroids. Gynesonics has developed the Sonata™ System for the transcervical treatment of symptomatic uterine fibroids under intrauterine sonography guidance. The Sonata™ System is CE Marked and approved for sale in the European Union. Sonata™ System is not available for sale in the United States. Gynesonics is a privately held company with headquarters in Redwood City, CA.
CONTACT: Chris Owens Gynesonics President and CEO +1.650.216.3860 www.gynesonics.com